oxonic acid

Summary

Summary: Antagonist of urate oxidase.

Top Publications

  1. Mochizuki I, Takiuchi H, Ikejiri K, Nakamoto Y, Kinugasa Y, Takagane A, et al. Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial. Br J Cancer. 2012;106:1268-73 pubmed publisher
    ..The incidences of ?grade 3 AEs were 16% and 14%, respectively. Although AE profiles differed between the groups, feasibility of the protocol treatment was good. Both S-1 and UFT/LV could be safely used as adjuvant chemotherapy. ..
  2. Nakashima T, Toh S, Shiratsuchi H, Yasumatsu R, Fukushima J, Nakamura K, et al. [Laryngeal preservation for hypopharyngeal cancer by radiotherapy with S-1 and vitamin A(TAR therapy)]. Gan To Kagaku Ryoho. 2012;39:759-63 pubmed
    ..4%). S- 1 is administered orally, and TAR therapy can be conducted in the clinic with low toxicity. However, protocols with high intensity may be necessary to improve laryngeal preservation for locally advanced(T4)hypopharyngeal cancer. ..
  3. Satoh T, Sakata Y. S-1 for the treatment of gastrointestinal cancer. Expert Opin Pharmacother. 2012;13:1943-59 pubmed publisher
    ..The excellent design of S-1 aimed to reduce toxicity by avoiding certain routes of degradation, and to enhance activity by reducing catabolism. This has provided not only a suitable alternative to 5-FU, but also higher efficacy. ..
  4. Hong Y, Park Y, Lim H, Lee J, Kim T, Kim K, et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol. 2012;13:1125-32 pubmed publisher
    ..Korea Healthcare Technology Research and Development Project, Ministry of Health and Welfare, South Korea. ..
  5. Hirakawa M, Sato Y, Ohnuma H, Takayama T, Sagawa T, Nobuoka T, et al. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker. Cancer Chemother Pharmacol. 2013;71:789-97 pubmed publisher
    ..The DDB2/ERCC1-high phenotype, as determined by immunohistochemistry, may be useful predictor of resistance to DCS chemotherapy. ..
  6. Araki H, Fukushima M, Kamiyama Y, Shirasaka T. Effect of consecutive lower-dose cisplatin in enhancement of 5-fluorouracil cytotoxicity in experimental tumor cells in vivo. Cancer Lett. 2000;160:185-91 pubmed
    ..Consecutive lower-dose CDDP also may be concluded to act as an important modulator of the enhancement of 5-FU cytotoxicity in experimental tumors. ..
  7. Kato T, Shimamoto Y, Uchida J, Ohshimo H, Abe M, Shirasaka T, et al. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil. Anticancer Res. 2001;21:1705-12 pubmed
    ..These results suggest that oral S-1 could be employed for the treatment of cancer patients with marked reduction in the incidence of toxicities including encephalopathy, stomatitis and diarrhea...
  8. Tsuji A, Shima Y, Morita S, Uchida M, Okamoto K, Morita M, et al. Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study. Anticancer Res. 2008;28:1433-8 pubmed
    ..6% (5/32). The combination of S-1 and low-dose twice-weekly cisplatin therapy appears to be highly efficacious and safe and shows promise as a useful treatment strategy, even in outpatient clinics. ..
  9. Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimada Y, et al. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer. 2003;89:816-20 pubmed
    ..The AUC(0-10 h) of FBAL was markedly lower and plasma uracil concentrations were significantly higher for S-1 than for PVI of 5-FU, clearly demonstrating the effect of DPD inhibition. ..

More Information

Publications103 found, 100 shown here

  1. Hyodo I, Nishina T, Moriwaki T, Endo S, Terao T, Hirao K, et al. A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting. Eur J Cancer. 2003;39:2328-33 pubmed
    ..Oral S-1 with weekly cisplatin is a feasible and promising combination regimen that is appropriate for an outpatient setting. A randomised phase II study comparing this combination with S-1 alone in chemo-nai;ve patients is warranted. ..
  2. Peters G, Noordhuis P, van Kuilenburg A, Schornagel J, Gall H, Turner S, et al. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. Cancer Chemother Pharmacol. 2003;52:1-12 pubmed
    S-1 is an oral formulation of ftorafur (FT), oxonic acid and 5-chloro-2,4-dihydroxypyridine (CDHP) at a molar ratio of 1:0.4:1...
  3. Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, et al. A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer. Oncology. 2009;77:300-3 pubmed publisher
    ..0%) and grade 3 anemia (6.3%). There were no grade 4 toxicities. Combination therapy with gemcitabine and S-1 using the modified 4-week schedule was well tolerated and efficacious for advanced pancreatic cancer. ..
  4. Jeung H, Rha S, Im C, Shin S, Ahn J, Yang W, et al. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Cancer. 2011;117:2050-7 pubmed publisher
    ..The findings suggest that split-dose weekly docetaxel alleviates hematological toxicity without compromising efficacy, and that SPARC expression may help individualize therapy in advanced gastric cancer. ..
  5. Yoshisue K, Hironaga K, Yamaguchi S, Yamamoto A, Nagayama S, Kawaguchi Y. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats. Cancer Chemother Pharmacol. 2000;46:51-6 pubmed
    ..Our results suggest that repeated simultaneous administration of Oxo and FT can effectively protect the activity of TS by decreasing FdUMP via FUMP from 5-FU in GI tissue, and may lead to a reduction in GI toxicity. ..
  6. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer. 2001;85:939-43 pubmed
    ..1 months. The one-year survival rates of the stage IIIB and IV patients were 30.7% and 47.4%, respectively. S-1 was considered to be an active single agent against NSCLC. Further study of S-1 with other active agents is warranted. ..
  7. Ajani J, Lee F, Singh D, Haller D, Lenz H, Benson A, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24:663-7 pubmed
    ..S-1 plus cisplatin is active against gastric cancer and has a favorable toxicity profile. A global phase III study of S-1 plus cisplatin versus fluorouracil plus cisplatin currently is accruing patients. ..
  8. Tahara M, Araki K, Okano S, Kiyota N, Fuse N, Minashi K, et al. Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer. Ann Oncol. 2011;22:175-80 pubmed publisher
    ..TPS was well tolerated. The recommended phase II dose as induction chemotherapy for locally advanced HNC was determined as 70/70/60 mg·m(2)/day every 3 weeks. Antitumor activity was highly promising and warrants further investigation. ..
  9. Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Hara T, Denda T, et al. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011;80:119-25 pubmed publisher
    ..This combination therapy seems to be an attractive alternative to conventional chemoradiotherapy using 5-fluorouracil infusion. ..
  10. Harada K, Kawaguchi S, Supriatno -, Onoue T, Yoshida H, Sato M. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol. 2004;40:713-9 pubmed
  11. Aoyama T, Yoshikawa T, Watanabe T, Hayashi T, Ogata T, Cho H, et al. Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1. Gastric Cancer. 2011;14:150-4 pubmed publisher
    ..The histological type was a significant prognosticator in patients who experienced recurrence after adjuvant S-1 therapy and thereafter received palliative chemotherapy. ..
  12. Konno H, Tanaka T, Baba M, Kanai T, Matsumoto K, Kamiya K, et al. Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma. Jpn J Cancer Res. 1999;90:448-53 pubmed
    ..6 times) and plasma (2.5 times) than UFT. These results suggest that S-1 will show a higher clinical therapeutic effect against human colorectal cancer than UFT. ..
  13. Yamamoto Y, Kino Y, Ohara K, Onuma S, Asai K, Kobayashi T, et al. [A case report of advanced cardiac cancer showing a complete response to TS-1 as neoadjuvant chemotherapy]. Gan To Kagaku Ryoho. 2004;31:579-83 pubmed
    ..In the future, TS-1 can be expected to display efficacy in neoadjuvant chemotherapy for patients with advanced gastric cancer who have poor prognoses. ..
  14. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer. Gastric Cancer. 2007;10:129-34 pubmed
    ..The results will facilitate safer administration of S-1 and thus promote enhanced tolerability and efficacy. ..
  15. Lenz H, Lee F, Haller D, Singh D, Benson A, Strumberg D, et al. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer. 2007;109:33-40 pubmed
    ..The efficacy against AGC, according to an external review, was encouraging. FLAGS is expected to complete its accrual of 1050 patients by December 2007. ..
  16. Nakahira S, Nakamori S, Tsujie M, Takeda S, Sugimoto K, Takahashi Y, et al. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts. Anticancer Res. 2008;28:179-86 pubmed
    ..Based on the effects of S-1 on the uptake of GEM, S-1 should be used before GEM treatment. The GEM/S-1 combination therapy in patients with pancreatic cancer may be promising and should be tested in clinical trials. ..
  17. Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol. 2010;28:5240-6 pubmed publisher
    ..Oral S-1 with carboplatin was noninferior in terms of OS compared with carboplatin and paclitaxel in patients with advanced NSCLC, and is thus a valid treatment option. ..
  18. Choi Y, Chung J, Shin H, Cho G, Wang S, Lee B, et al. Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. J Laryngol Otol. 2008;122:848-53 pubmed
    ..S-1 plus cisplatin combination chemotherapy is effective against locally advanced squamous cell carcinoma of the head and neck, with only mild toxicity. ..
  19. Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol. 2008;62:849-55 pubmed publisher
    ..5%), anorexia (7.5%) and T-Bil elevation (7.5%). Significant antitumor activity combined with a mild toxicity profile was observed. This monotherapy warrants further evaluation in a randomized study. ..
  20. Lee G, Kim H, Ju J, Kim S, Kim H, Kim T, et al. Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2009;64:707-13 pubmed publisher
    ..6%). The combination chemotherapy of S-1 and gemcitabine showed promising antitumor activity and manageable toxicities, and especially for the good performance status patients with unresectable pancreatic cancer. ..
  21. Kinoshita T, Nashimoto A, Yamamura Y, Okamura T, Sasako M, Sakamoto J, et al. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. Gastric Cancer. 2004;7:104-9 pubmed
    ..Except for the early development of anorexia, most likely due to adverse effects of surgery, postoperative administration of S-1 for 1 year seems feasible as adjuvant chemotherapy for gastric cancer. ..
  22. Atagi S, Kawahara M, Kusunoki Y, Takada M, Kawaguchi T, Okishio K, et al. Phase I/II study of docetaxel and S-1 in patients with previously treated non-small cell lung cancer. J Thorac Oncol. 2008;3:1012-7 pubmed publisher
    ..This combination chemotherapy is highly active and well tolerated in previously treated patients with non-small cell lung cancer. These results are encouraging and warrant additional investigation. ..
  23. Takahashi I, Emi Y, Kakeji Y, Tokunaga E, Ushiro S, Oki E, et al. Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer. Oncol Rep. 2006;15:849-54 pubmed
    ..The dose limiting toxicity of a combination of S-1 and biweekly DOC was leukopenia and neutropenia. The recommended dose for this combination in phase II study is DOC 35 mg/m2/day. ..
  24. Tsutani Y, Ohara M, Suzuki T, Minami K, Miyahara E, Kameda A, et al. Docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer. Anticancer Res. 2009;29:2775-9 pubmed
    ..No treatment-related death was observed. Docetaxel plus S-1 combination is an active and tolerable regimen as a first-line treatment in patients with advanced or recurrent gastric cancer. ..
  25. Fukushima M, Sakamoto K, Ohshimo H, Nakagawa F, Taguchi T. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase. Oncol Rep. 2010;24:835-42 pubmed
    ..These findings suggest that CPT-11, but not l-OHP, would overcome the resistance to 5-FU in combination with 5-FU pro-drugs on 5-FU-resistant colon tumors. ..
  26. Fujiwara Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, et al. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol. 2012;105:38-42 pubmed publisher
    ..This study evaluated the benefits of this combination chemotherapy and subsequent surgery...
  27. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 2006;94:1575-9 pubmed
    ..Median survival and 1-year survival rate were 12.5 months (95% CI, 5.9-19.1) and 54% (95% CI, 36-72), respectively. Combination chemotherapy with GEM and S-1 was well tolerated and yielded a significantly high response rate. ..
  28. Fushida S, Fujimura T, Oyama K, Yagi Y, Kinoshita J, Ohta T. Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases. Anticancer Drugs. 2009;20:752-6 pubmed publisher
    ..This preoperative DCS therapy was considered feasible and provided a high pathological response rate in gastric cancer patients with para-aortic lymph node metastases. ..
  29. Nonoshita T, Shioyama Y, Nakamura K, Nakashima T, Ohga S, Yoshitake T, et al. Concurrent chemoradiotherapy with S-1 for T2N0 glottic squamous cell carcinoma. J Radiat Res. 2010;51:481-4 pubmed
    ..Chemoradiotherapy with S-1 was feasible, well tolerated and effective. This therapy is suggested as a possible regimen for improving local control of T2N0 glottic carcinoma...
  30. Park S, Kong S, Rhee J, Park Y, Ryu K, Lee J, et al. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Ann Oncol. 2011;22:890-6 pubmed publisher
    ..The TIROX regimen induced marked tumor reduction and promising survival with a manageable toxicity profile in MGC patients. UGT1A genotype may be predictive of TIROX toxicity. ..
  31. Tahara M, Minami H, Kawashima M, Kawada K, Mukai H, Sakuraba M, et al. Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck. Cancer Sci. 2011;102:419-24 pubmed publisher
    ..Administration of S-1 as a suspension or by whole capsule can be considered therapeutically interchangeable. Although these data are preliminary, activity was highly promising, and this approach warrants further investigation. ..
  32. Van den Brande J, Schoffski P, Schellens J, Roth A, Duffaud F, Weigang Köhler K, et al. EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer. 2003;88:648-53 pubmed
    ..The other toxicities were limited and manageable. S-1 is active in advanced colorectal cancer, but in order to establish a safer dose the drug should be subject to further investigations. ..
  33. Kawai H, Ohtsu A, Boku N, Hamamoto Y, Nagashima F, Muto M, et al. Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey. Gastric Cancer. 2003;6 Suppl 1:19-23 pubmed
    ..S-1 appears to be safe and highly active, with favorable longterm survival in patients with metastatic gastric cancer, particularly in those with diffuse-type histology and peritoneal metastasis. ..
  34. Inokuchi M, Yamashita T, Yamada H, Kojima K, Ichikawa W, Nihei Z, et al. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer. 2006;94:1130-5 pubmed
    ..The RR was 62% (26 of 42, 95% confidence interval: 47.2-76.6%), and the median survival time was 444 days. Our phase I/II trial showed S-1 combined with CPT-11 is effective for AGC and is well tolerated, with acceptable toxicity. ..
  35. Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N, et al. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol. 2011;67:1423-8 pubmed publisher
    ..This treatment should be considered as a feasible experimental arm for the next postoperative adjuvant phase III trial. ..
  36. Park I, Lee J, Ryu M, Kim T, Chang H, Lee S, et al. Efficacy and safety of S-1 monotherapy in patients with advanced biliary tract adenocarcinoma: retrospective analysis of 162 patients. Oncology. 2009;76:126-32 pubmed publisher
    ..S-1 has a favorable toxicity profile and can be safely administered to BTA patients with hyperbilirubinemia. The efficacy of S-1 against advanced BTA depends on the tumor site and is most effective in patients with extrahepatic BTA. ..
  37. Nakayama T, Morita S, Takashima T, Kamigaki S, Yoshidome K, Ito T, et al. Phase I study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer. Anticancer Res. 2011;31:3035-9 pubmed
    ..S-1 plus trastuzumab could be safely and effectively used for the treatment of HER2-positive MBC. The RD for a phase II study of this regimen was determined to be 80 mg/m² S-1 and 2 mg/kg trastuzumab every week (loading dose, 4 mg/kg). ..
  38. Suto A, Kubota T, Fukushima M, Ikeda T, Takeshita T, Ohmiya H, et al. Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice. Oncol Rep. 2006;15:1517-22 pubmed
    ..Down-regulation of the DPD activity of the tumors is also considered to be correlated with the antitumor effect of the treated groups, suggesting its influence on the synergistic effect of the combination therapy. ..
  39. Ikeda M, Okusaka T, Ito Y, Ueno H, Morizane C, Furuse J, et al. A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. Br J Cancer. 2007;96:1650-5 pubmed
    ..0 months, respectively. The recommended dose of S-1 therapy with concurrent radiotherapy is 80 mg m(-2) day(-1). A multi-institutional phase II trial of this regimen in patients with locally advanced pancreatic cancer is now underway. ..
  40. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-21 pubmed publisher
    ..There were no treatment-related deaths in either group. S-1 plus cisplatin holds promise of becoming a standard first-line treatment for patients with advanced gastric cancer. ..
  41. Oh D, Cha Y, Choi I, Yoon S, Choi I, Kim J, et al. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Cancer Chemother Pharmacol. 2010;65:527-36 pubmed publisher
    ..5%), stomatitis (2.6%), rash (7.9%), fatigue (7.9%) and hyperbilirubinemia (5.3%). Gemcitabine and S-1 combination chemotherapy was effective and tolerable in patients with unresectable pancreatic cancer. ..
  42. Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer. 2011;14:72-80 pubmed publisher
    ..Although IRI-S achieved longer median survival than S-1 monotherapy and was well tolerated, it did not show significant superiority in this study. ..
  43. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993;53:4004-9 pubmed
    ..b>Oxonic acid was found to inhibit the phosphorylation of 5-FU to 5-fluorouridine-5'-monophosphate catalyzed by pyrimidine ..
  44. Saeki T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, et al. [A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer]. Gan To Kagaku Ryoho. 2004;31:539-47 pubmed
    ..Therefore, S-1 may be a new therapeutic agent to prolong the survival period of breast cancer patients due to its high antitumor activity and low toxicity...
  45. Takiuchi H, Narahara H, Tsujinaka T, Gotoh M, Kawabe S, Katsu K, et al. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002). Jpn J Clin Oncol. 2005;35:520-5 pubmed
    ..There were no significant differences between the PK parameters of S-1 on days 10 and 15. S-1 with CPT-11 can be combined safely without CPT-11 effect on S-1 PK data and holds promise as an effective regimen for advanced gastric cancer. ..
  46. Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, et al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol. 2007;37:843-51 pubmed
    ..The adjusted hazard ratio for GEM in the Cox regression was 0.53 (95% CI 0.34-0.82) and the hazard ratio for the CDDP-based regimen was 0.49 (95% CI 0.36-0.99). Chemotherapy with GEM may benefit patients with BTC. ..
  47. Kubota K, Sakai H, Yamamoto N, Kunitoh H, Nakagawa K, Takeda K, et al. A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010;5:702-6 pubmed publisher
    ..1%). CDDP combined with S-1 showed a satisfactory overall survival time and acceptable toxicity profile. However, the response as the primary end point did not reach the predetermined threshold level. ..
  48. Nakai Y, Isayama H, Sasaki T, Sasahira N, Kogure H, Hirano K, et al. Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan. Jpn J Clin Oncol. 2010;40:774-80 pubmed publisher
    ..The introduction of S-1 might improve the prognosis of patients with gemcitabine-refractory pancreatic cancer. ..
  49. Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res. 2004;10:7860-4 pubmed
    ..These results warrant further investigations of this regimen including a randomized controlled trial for its use as a first line treatment for NSCLC. ..
  50. Harada K, Kawaguchi S, Supriatno -, Kawashima Y, Yoshida H, Sato M. S-1, an oral fluoropyrimidine anti-cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: involvement possibility of inhibition of survival signal, Akt/PKB. Cancer Lett. 2005;226:161-168 pubmed
    ..Survival signals Akt/PKB may be involved in determining radiosensitivity. S-1, an oral fluoropyrimidine anti-cancer agent can exert the enhancing effect on radiation by suppressing the activation of Akt/PKB. ..
  51. Kim M, Lee K, Jang B, Kim T, Eun J, Bae S, et al. S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer. Jpn J Clin Oncol. 2009;39:49-53 pubmed publisher
    ..Twenty patients (91%) received chemotherapy on an outpatient basis. Combination chemotherapy of S-1 plus gemcitabine appears to be active and well tolerated as first-line treatment in patients with advanced/metastatic pancreatic cancer. ..
  52. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387-93 pubmed publisher
    ..On the basis of 5-year follow-up data, postoperative adjuvant therapy with S-1 was confirmed to improve overall survival and relapse-free survival in patients with stage II or III gastric cancer who had undergone D2 gastrectomy. ..
  53. Fujiwara H, Terashima M, Irinoda T, Takagane A, Abe K, Nakaya T, et al. Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity. Eur J Cancer. 2003;39:2387-94 pubmed
    ..The superior cytotoxicity of S-1 appears to be attributable to both an increased inhibition of DNA synthesis and an enhanced blockade of RNA function against tumours with a high DPD activity. ..
  54. Tsukuda M, Ishitoya J, Mikami Y, Matsuda H, Horiuchi C, Taguchi T, et al. Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. Cancer Chemother Pharmacol. 2009;64:945-52 pubmed publisher
    ..Concurrent chemoradiotherapy with S-1 is a safe, well-tolerated and effective regimen for locally advanced SCCHN in elderly cases and/or cases with comorbidity. ..
  55. Kim Y, Im S, Kim H, Oh S, Lee K, Choi I, et al. A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Ann Oncol. 2008;19:99-103 pubmed
    ..7% of all cycles). Combination chemotherapy with S-1 and cisplatin was a moderately effective outpatient-based regimen in BTC patients. Toxic effects were moderate but manageable. ..
  56. Fujii M, Tomita K, Nishijima W, Tsukuda M, Hasegawa Y, Ishitoya J, et al. Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer. Jpn J Clin Oncol. 2010;40:214-21 pubmed publisher
    ..1%. The main toxicities of Grade 3 or above were anorexia (26.5%), nausea (14.7%), neutropenia/thrombocytopenia (11.8%) and anemia/fatigue (8.8%). This is considered to be an effective regimen with acceptable toxicities for HNC. ..
  57. Sato Y, Takayama T, Sagawa T, Takahashi Y, Ohnuma H, Okubo S, et al. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol. 2010;66:721-8 pubmed publisher
    ..DCS combination chemotherapy is highly active against unresectable metastatic gastric cancer and can be given safely with proper management of adverse events. Further studies of this combination are warranted. ..
  58. Cohen S, Leichman C, Yeslow G, Beard M, Proefrock A, Roedig B, et al. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin Cancer Res. 2002;8:2116-22 pubmed
    ..and pharmacokinetics of S-1, a combination of tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and oxonic acid, administered once daily in patients with advanced cancer...
  59. Maehara Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer. 2003;6 Suppl 1:2-8 pubmed
    ..Thus, S-1 is currently the first candidate as the standard anticancer drug for gastric cancer. Further evaluations by well-controlled clinical trials are still needed. ..
  60. Zhu A, Clark J, Ryan D, Meyerhardt J, Enzinger P, Earle C, et al. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Cancer Chemother Pharmacol. 2007;59:285-93 pubmed
    S-1 is a novel oral fluoropyrimidine that combines tegafur with CDHP and oxonic acid. To decrease the incidence of late onset, severe diarrhea observed in a previous study, a phase I study was conducted to determine the maximum tolerated ..
  61. Sasaki T, Isayama H, Yashima Y, Yagioka H, Kogure H, Arizumi T, et al. S-1 monotherapy in patients with advanced biliary tract cancer. Oncology. 2009;77:71-4 pubmed publisher
    ..3%), anemia (6.9%), thrombocytopenia (10.3%) and total bilirubin elevation (3.4%). S-1 monotherapy is a feasible and moderately efficacious treatment for advanced biliary tract cancer, as a first- or second-line chemotherapy regimen. ..
  62. Tsuji H, Kiba T, Nagata M, Inoue T, Yukawa H, Yamashita T, et al. A phase I study of concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma. Oncology. 2006;71:369-73 pubmed
    ..Endpoints of this study were to examine the toxicity profile of this regimen and to determine the recommended dose of S-1...
  63. Takiuchi H, Goto M, Imamura H, Furukawa H, Imano M, Imamoto H, et al. Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302). Jpn J Clin Oncol. 2008;38:176-81 pubmed publisher
    ..Severe adverse events were found in three patients to discontinue the present treatment. The combination of paclitaxel and doxifluridine might be a treatment of choice as a second line chemotherapy for patient undergone S-1 treatment. ..
  64. Fujii M. Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). Int J Clin Oncol. 2008;13:201-5 pubmed publisher
    ..We are expecting full enrollment at the end of August 2008. The JACCRO GC-03 study is now ongoing. After 2 years follow-up from full enrollment, in 2010 we will report the final results of this study. ..
  65. Nakayama M, Hayakawa K, Okamoto M, Niibe Y, Ishiyama H, Kotani S. Phase I/II trial of concurrent use of S-1 and radiation therapy for T2 glottic cancer. Jpn J Clin Oncol. 2010;40:921-6 pubmed publisher
    ..The treatment strategy employing orally available S-1 proved to be beneficial over the conventional injection of antitumor agents for maintaining the patients' quality of life. ..
  66. Kodera Y, Ishiyama A, Yoshikawa T, Kinoshita T, Ito S, Yokoyama H, et al. A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703). Gastric Cancer. 2010;13:197-203 pubmed publisher
    ..The median progression-free survival time of all patients was 363 days. Although promising in the neoadjuvant and advanced/metastatic setting, S-1/CDDP is too toxic as a postgastrectomy treatment for Japanese patients. ..
  67. Ohnishi K, Shioyama Y, Nakamura K, Nakashima T, Ohga S, Nonoshita T, et al. Concurrent chemoradiotherapy with S-1 as first-line treatment for patients with oropharyngeal cancer. J Radiat Res. 2011;52:47-53 pubmed
    ..The treatment-related toxicities were acceptable, and the incidence of myelotoxicity was low. Further study must be carried out to compare with other chemotherapy regimens. ..
  68. Nakamura M, Maruyama K, Furukawa J, Maruyama N, Tanaka J, Katsumoto Y, et al. [TS-1/CDDP therapy for advanced gastric cancer as neoadjuvant chemotherapy]. Gan To Kagaku Ryoho. 2002;29:1823-8 pubmed
    ..0%. Stomach, liver, lymph node and peritoneal tumors responded to TS-1/CDDP. TS-1/CDDP therapy produces a high response in cases of gastric cancer, and it is useful as a neoadjuvant chemotherapy. ..
  69. Saek T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, et al. A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer. 2004;11:194-202 pubmed
    ..S-1 was demonstrated to have high efficacy with low gastrointestinal toxicity even in older patients and will be a promising new chemotherapy drug for metastatic breast cancer. ..
  70. Takayama T, Sato Y, Sagawa T, Okamoto T, Nagashima H, Takahashi Y, et al. Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Br J Cancer. 2007;97:851-6 pubmed
    ..Three of these have been disease free for about 3 years, suggesting a complete cure. In conclusion, this regimen was tolerable and showed a quite high RR, with an appreciable downstaging rate in metastatic gastric cancer. ..
  71. Zang D, Yang D, Lee H, Hwang S, Song H, Jung J, et al. Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age. Cancer Chemother Pharmacol. 2009;63:509-16 pubmed publisher
    ..The overall response rate was 50% (95% CI, 35-66%) and median survival was 15.3 months (95% CI, 10.0-20.6 months). Combination with docetaxel and S-1 was active against advanced gastric cancer and gave manageable toxicities. ..
  72. Totani Y, Saito Y, Hayashi M, Tada T, Kohashi Y, Mieno Y, et al. A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2009;64:1181-5 pubmed publisher
    ..1%). Grade 3 non-hematological toxicities were observed in only five patients (10.4%). Treatment-related death did not occur. S-1 is an active and well-tolerated monotherapy for second-line treatment of advanced NSCLC. ..
  73. Yanagihara K, Yoshimura K, Niimi M, Yasuda H, Sasaki T, Nishimura T, et al. Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer. Cancer Chemother Pharmacol. 2010;66:913-8 pubmed publisher
    ..A phase III trial comparing docetaxel with or without S-1 would warrant further investigation. ..
  74. Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol. 2010;11:853-60 pubmed publisher
    ..Treatment with IRIS could be an additional therapeutic option for second-line chemotherapy in metastatic colorectal cancer. Taiho Pharmaceutical Co Ltd and Daiichi Sankyo Co Ltd. ..
  75. Chuah B, Goh B, Lee S, Soong R, Lau F, Mulay M, et al. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci. 2011;102:478-83 pubmed publisher
    ..59; P = 0.002). Grade 3/4 gastrointestinal toxicities were more common in Caucasians than Asians (21%vs 0%). Treatment with S-1 yields no significant difference in 5FU exposure between Caucasians and East Asians. ..
  76. Fujitani K, Narahara H, Takiuchi H, Tsujinaka T, Satomi E, Gotoh M, et al. Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. Oncology. 2005;69:414-20 pubmed
    ..This regimen could represent a novel and low toxic combination for advanced gastric cancer. ..
  77. Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H, et al. Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer. 2006;94:1803-8 pubmed
    ..3-17.3 months), respectively. The most common grade 3/4 toxicity was neutropenia (67% of patients), which was predictable and manageable. This regimen showed promising activity with moderate toxicities in advanced gastric cancer. ..
  78. Koizumi W, Boku N, Yamaguchi K, Miyata Y, Sawaki A, Kato T, et al. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. Ann Oncol. 2010;21:766-71 pubmed publisher
    ..S-1 combined with LV therapy demonstrated promising efficacy and acceptable safety in chemotherapy-naive patients with mCRC without the concurrent use of irinotecan, oxaliplatin, or molecular-targeted drugs. ..
  79. Choi I, Lee K, Kim K, Kim Y, Kim J, Lee J. Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer. Med Oncol. 2010;27:992-7 pubmed publisher
    ..No treatment-related mortality occurred. Three-weekly S-1/cisplatin chemotherapy was active and well-tolerated in MRGC patients. ..
  80. Ajani J, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28:1547-53 pubmed publisher
    ..5% v 4.9%; P < .05). Cisplatin/S-1 did not prolong OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/infusional fluorouracil, but it did result in a significantly improved safety profile. ..
  81. Yoshikawa T, Omura K, Kobayashi O, Nashimoto A, Takabayashi A, Yamada T, et al. A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). Eur J Surg Oncol. 2010;36:546-51 pubmed publisher
    ..There was no surgical mortality. Operative morbidity occurred in 5 of 49 patients, including pancreatic fistula in 1 and abdominal abscess in 2. This multi-modality treatment seems to be feasible and safe for T3-4 gastric cancer. ..
  82. Oki Y, Hirose T, Yamaoka T, Kusumoto S, Shirai T, Sugiyama T, et al. Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2011;67:791-7 pubmed publisher
    ..The combination of S-1 and biweekly docetaxel is an acceptable therapeutic option in patients with previously treated advanced NSCLC regardless of the histological type. ..
  83. Chu Q, Hammond L, Schwartz G, Ochoa L, Rha S, Denis L, et al. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res. 2004;10:4913-21 pubmed
    ..CDHP)], and an inhibitor of orotate phosphoribosyltransferase [potassium oxonate (oxonic acid)], was developed to increase the feasibility and therapeutic index of 5-FU administered orally...
  84. Ueno H, Okusaka T, Ikeda M, Ishiguro Y, Morizane C, Matsubara J, et al. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology. 2005;69:421-7 pubmed
    ..We recommend a gemcitabine dose of 1,000 mg/m(2)/week and an S-1 dose of 80 mg/m(2)/day in further studies with this schedule. ..
  85. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res. 2006;12:3402-7 pubmed
    ..Docetaxel/S-1 combination is highly active and well tolerated in advanced or recurrent gastric cancer. Further investigation in randomized studies is warranted. ..
  86. Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, et al. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer. 2008;98:832-9 pubmed publisher
    ..00 (1.001-1.002)) were significant predictors of poor survival. Our results suggest that these biomarkers are useful predictors of clinical outcomes in patients with advanced GC. ..
  87. Kodera Y, Ito S, Mochizuki Y, Kondo K, Koshikawa K, Suzuki N, et al. A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). Eur J Surg Oncol. 2009;35:1158-63 pubmed publisher
    ..A standard treatment for such patients remains to be established...
  88. Katsumata N, Hirai Y, Kamiura S, Sugiyama T, Kokawa K, Hatae M, et al. Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer. Ann Oncol. 2011;22:1353-7 pubmed publisher
    ..Phase III studies of S-1 in patients with advanced or recurrent cervical cancer are thus warranted. ..
  89. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000;58:191-7 pubmed
    ..S-1 is effective against advanced gastric cancer. This oral treatment is suitable for outpatients because of its mild toxicity. Further therapeutic benefits are likely to be obtained by combining S-1 with other chemotherapeutic agents. ..
  90. van Groeningen C, Peters G, Schornagel J, Gall H, Noordhuis P, de Vries M, et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol. 2000;18:2772-9 pubmed
    ..In heavily pretreated patients, the recommended dose is 35 mg/m(2) bid. Phase II trials are warranted in tumors known to be responsive to 5-FU treatment. ..
  91. Mori T, Fujiwara Y, Yano M, Tamura S, Yasuda T, Takiguchi S, et al. Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil. Oncology. 2003;64:176-82 pubmed
    ..The area under the curve of 5-FU in tumor was higher than in the peritoneum and plasma. Oral S-1 is a promising chemotherapy for peritoneal dissemination of gastric cancer. ..
  92. Fujii M. [Combination therapy with S-1 and CDDP for head and neck cancer]. Gan To Kagaku Ryoho. 2006;33 Suppl 1:150-4 pubmed
    ..The efficacy and adverse effects of CDDP plus S-1 should be studied in carefully designed phase II/III trials. S-1 will be one of the key drugs for HNSCC in the future. ..